PureTech Health plc (LON:PRTC - Get Free Report)'s share price fell 15.2% during trading on Tuesday . The company traded as low as GBX 117.20 ($1.53) and last traded at GBX 117.20 ($1.53). 42,764,352 shares traded hands during trading, an increase of 2,645% from the average session volume of 1,557,904 shares. The stock had previously closed at GBX 138.20 ($1.81).
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group restated a "buy" rating and set a GBX 455 ($5.95) price objective on shares of PureTech Health in a research report on Monday, December 16th.
View Our Latest Stock Analysis on PureTech Health
PureTech Health Stock Performance
The firm has a market capitalization of £354.45 million, a PE ratio of -4.84 and a beta of 1.02. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82. The business's 50 day simple moving average is GBX 135.24 and its two-hundred day simple moving average is GBX 148.09.
PureTech Health Company Profile
(
Get Free Report)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
See Also
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
